Research Analysts Offer Predictions for KYMR Q3 Earnings

Kymera Therapeutics, Inc. (NASDAQ:KYMR) – Investment analysts at Brookline Capital Markets cut their Q3 2026 earnings per share estimates for Kymera Therapeutics in a research report issued on Wednesday, August 5th. Brookline Capital Markets analyst L. Cann now expects that the company will post earnings of ($1.31) per share for the quarter, down from their previous estimate of ($1.11). Brookline Capital Markets has a “Buy” rating on the stock. The consensus estimate for Kymera Therapeutics’ current full-year earnings is ($3.29) per share. Brookline Capital Markets also issued estimates for Kymera Therapeutics’ Q4 2026 earnings at ($1.33) EPS, FY2026 earnings at ($3.97) EPS, FY2027 earnings at ($5.28) EPS, FY2028 earnings at ($6.18) EPS and FY2029 earnings at ($5.61) EPS.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.62) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.09. The company had revenue of $65.00 million for the quarter, compared to the consensus estimate of $32.78 million. Kymera Therapeutics had a negative net margin of 285.33% and a negative return on equity of 21.82%. The firm’s quarterly revenue was up 465.2% compared to the same quarter last year. During the same period last year, the company posted ($0.95) EPS.

KYMR has been the topic of a number of other research reports. Wall Street Zen raised shares of Kymera Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 2nd. Loop Capital set a $97.00 price target on Kymera Therapeutics in a research note on Monday, June 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Kymera Therapeutics in a report on Friday, July 17th. Royal Bank Of Canada downgraded Kymera Therapeutics from an “outperform” rating to a “sector perform” rating and raised their price objective for the company from $106.00 to $115.00 in a report on Monday, July 13th. Finally, Canaccord Genuity Group upped their target price on Kymera Therapeutics from $106.00 to $129.00 and gave the stock a “buy” rating in a report on Friday, June 26th. Twenty equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $125.65.

Kymera Therapeutics Price Performance

KYMR stock opened at $106.41 on Friday. The stock has a market cap of $8.75 billion, a price-to-earnings ratio of -32.84 and a beta of 1.95. The company has a 50 day simple moving average of $100.79 and a 200 day simple moving average of $88.66. Kymera Therapeutics has a 1 year low of $36.65 and a 1 year high of $130.05.

Institutional Investors Weigh In On Kymera Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in KYMR. State of New Jersey Common Pension Fund D bought a new stake in Kymera Therapeutics in the fourth quarter worth approximately $2,610,000. Vanguard Group Inc. boosted its holdings in shares of Kymera Therapeutics by 15.6% during the 4th quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock worth $487,685,000 after buying an additional 845,922 shares in the last quarter. Maven Securities LTD acquired a new stake in shares of Kymera Therapeutics during the 4th quarter worth approximately $1,167,000. Eagle Health Investments LP acquired a new stake in shares of Kymera Therapeutics during the 4th quarter worth approximately $10,606,000. Finally, Monashee Investment Management LLC bought a new stake in shares of Kymera Therapeutics in the 4th quarter valued at $7,781,000.

Insider Buying and Selling at Kymera Therapeutics

In related news, Director Bruce Booth sold 467,878 shares of the firm’s stock in a transaction on Friday, June 26th. The stock was sold at an average price of $110.29, for a total transaction of $51,602,264.62. Following the completion of the transaction, the director directly owned 472,267 shares of the company’s stock, valued at $52,086,327.43. This trade represents a 49.77% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Nello Mainolfi sold 80,000 shares of the firm’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $115.29, for a total value of $9,223,200.00. Following the transaction, the chief executive officer directly owned 666,568 shares of the company’s stock, valued at approximately $76,848,624.72. This represents a 10.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 3,607,813 shares of company stock worth $387,818,004 in the last three months. 15.98% of the stock is currently owned by company insiders.

More Kymera Therapeutics News

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Kymera reported a second-quarter loss of $0.62 per share, narrower than the consensus estimate of a $0.71 loss and improved from a $0.95 loss a year earlier. Revenue reached $65.0 million versus analyst expectations of $32.78 million, representing 465% year-over-year growth. KYMR Q2 results
• Positive Sentiment: Revenue was boosted by milestone payments from partners Gilead Sciences and Sanofi, while the company continues advancing KT-621, its STAT6 degrader. The payments and better cost performance provide near-term financial support. Q2 earnings and revenue beat
• Positive Sentiment: Enrollment in the BROADEN2 Phase 2b trial of KT-621 in atopic dermatitis finished nearly six months ahead of schedule. Kymera expects topline data by year-end 2026, a potentially important catalyst for the stock, and plans to begin Phase 3 studies by mid-2027. Second-quarter results and business update
• Positive Sentiment: Kymera ended June with approximately $1.5 billion in cash and expects its runway to extend into 2029, reducing near-term financing and dilution risk while it develops KT-621, KT-579 and partnered KT-485.
• Neutral Sentiment: Additional catalysts include KT-579 Phase 1 data expected in the fourth quarter of 2026 and KT-621 asthma data anticipated in late 2027. However, the investment case remains dependent on clinical efficacy and safety results that have not yet been reported. KT-621 data and cash runway
• Negative Sentiment: Although the quarterly loss narrowed, Kymera remains unprofitable, and a substantial portion of the revenue beat came from milestone payments that may not recur each quarter. The company is still forecast to post a full-year loss.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical?stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small?molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease?causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.